Investigational agents for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: progress in clinical trials

References

• Laupland KB. Incidence of bloodstream infection: a review of population-based studies. Clin Microbiol Infect. 2013 Jun;19(6):492–500.
   PubMed Web of Science ®Google Scholar
• Bearman GM, Wenzel RP. Bacteremias: a leading cause of death. Arch Med Res. 2005 Nov-Dec;36(6):646–659.
   PubMed Web of Science ®Google Scholar
• David MZ, Daum RS, Bayer AS, et al. Staphylococcus aureus bacteremia at 5 US academic medical centers, 2008-2011: significant geographic variation in community-onset infections. Clin Infect Dis. 2014 Sep 15;59(6):798–807.
   PubMed Web of Science ®Google Scholar
• Kaasch AJ, Barlow G, Edgeworth JD, et al. Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies. J Infect. 2014 Mar;68(3):242–251.
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Jensen SO, Vaska VL, et al. Predictors of mortality in staphylococcus aureus bacteremia. Clin Microbiol Rev. 2012 Apr;25(2):362–386.
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36(1):53–59.
   PubMed Web of Science ®Google Scholar
• Kourtis AP, Hatfield K, Baggs J, et al. Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible staphylococcus aureus bloodstream infections - United States. MMWR Morb Mortal Wkly Rep. 2019 Mar 8;68(9):214–219.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Trecarichi EM, Mesini A, et al. Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2012 Sep;18(9):862–869.
   PubMed Web of Science ®Google Scholar
• Anantha RV, Jegatheswaran J, Pepe DL, et al. Risk factors for mortality among patients with Staphylococcus aureus bacteremia: a single-centre retrospective cohort study. CMAJ Open. 2014 Oct;2(4):E352–9.
   PubMedGoogle Scholar
• Austin ED, Sullivan SS, Macesic N, et al. Reduced mortality of Staphylococcus aureus bacteremia in a retrospective cohort study of 2139 patients: 2007-2015. Clin Infect Dis. 2020 Apr 10;70(8):1666–1674.
   PubMed Web of Science ®Google Scholar
• Horino T, Hori S. Metastatic infection during Staphylococcus aureus bacteremia. J Infect Chemother. 2020;26(2):162–169.
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, and Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011 Feb 1;52(3):e18–55.
   PubMed Web of Science ®Google Scholar
• Patel S, Preuss CV, Bernice F, Vancomycin, StatPearls, 2021; Treasure Island (FL)
   Google Scholar
• van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013 Feb;57(2):734–744.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim KH, Kim HB, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2008 Jan;52(1):192–197.
   PubMed Web of Science ®Google Scholar
• Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42:S35–S39.
   PubMed Web of Science ®Google Scholar
• Aljohani S, Layqah L, Masuadi E, et al. Occurrence of vancomycin MIC creep in methicillin resistant isolates in Saudi Arabia. J Infect Public Health. 2020 Oct;13(10):1576–1579.
   PubMed Web of Science ®Google Scholar
• Kehrmann J, Kaase M, Szabados F, et al. Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem? Eur J Clin Microbiol Infect Dis. 2011 May;30(5):677–683.
   PubMed Web of Science ®Google Scholar
• Diaz R, Afreixo V, Ramalheira E, et al. Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections-a systematic review and meta-analysis. Clin Microbiol Infect. 2018 Feb;24(2):97–104.
   PubMed Web of Science ®Google Scholar
• Prakash V, Lewis JS II, Jorgensen JH. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother. 2008 Dec;52(12):4528.
   PubMed Web of Science ®Google Scholar
• Edwards B, Milne K, Lawes T, et al. Is vancomycin MIC “creep” method dependent? analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. J Clin Microbiol. 2012 Feb;50(2):318–325.
   PubMed Web of Science ®Google Scholar
• Sader HS, Fey PD, Limaye AP, et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother. 2009 Oct;53(10):4127–4132.
   PubMed Web of Science ®Google Scholar
• Tenover FC, Moellering RC Jr. The rationale for revising the clinical and laboratory standards institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007 May 1;44(9):1208–1215.
   PubMed Web of Science ®Google Scholar
• Howden BP, Davies JK, Johnson PD, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010 Jan;23(1):99–139.
   PubMed Web of Science ®Google Scholar
• McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus. Yale J Biol Med. 2017 Jun;90(2):269–281.
   PubMed Web of Science ®Google Scholar
• Butler MS, Hansford KA, Blaskovich MA, et al. Glycopeptide antibiotics: back to the future. J Antibiot (Tokyo). 2014 Sep;67(9):631–644.
   PubMed Web of Science ®Google Scholar
• Shariati A, Dadashi M, Moghadam MT, et al. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis. Sci Rep. 2020 Jul 29;10(1):12689.
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012 Mar;54(6):755–771.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008 Sep;52(9):3315–3320.
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004 Jun;42(6):2398–2402.
   PubMed Web of Science ®Google Scholar
• Adani S, Bhowmick T, Weinstein MP, et al. Impact of vancomycin MIC on clinical outcomes of patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin at an institution with suppressed MIC reporting. Antimicrob Agents Chemother. 2018 Apr;62(4). DOI:https://doi.org/10.1128/AAC.02512-17
   Google Scholar
• Yeh YC, Yeh KM, Lin TY, et al. Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia. J Microbiol Immunol Infect. 2012 Jun;45(3):214–220.
   PubMedGoogle Scholar
• Zhang S, Sun X, Chang W, et al. Systematic review and meta-analysis of the epidemiology of vancomycin-intermediate and heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. PLoS One. 2015;10(8):e0136082.
   PubMed Web of Science ®Google Scholar
• Miller WR, Bayer AS, Arias CA. Mechanism of action and Resistance to daptomycin in Staphylococcus aureus and Enterococci. Cold Spring Harb Perspect Med. 2016 Nov 1;6(11). DOI:https://doi.org/10.1101/cshperspect.a026997
   Google Scholar
• Grein F, Muller A, Scherer KM, et al. Ca(2+)-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids. Nat Commun. 2020 Mar 19;11(1):1455.
   PubMed Web of Science ®Google Scholar
• Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009 Jul 15;49(2):177–180.
   PubMed Web of Science ®Google Scholar
• Falcone M, Russo A, Venditti M, et al. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2013 Dec;57(11):1568–1576.
   PubMed Web of Science ®Google Scholar
• Fowler VG Jr., Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006 Aug 17;355(7):653–665.
   PubMed Web of Science ®Google Scholar
• Patel N, Lubanski P, Ferro S, et al. Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009 Dec;53(12):5141–5144.
   PubMed Web of Science ®Google Scholar
• Humphries RM, Pollett S, Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev. 2013 Oct;26(4):759–780.
   PubMed Web of Science ®Google Scholar
• Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005 Jun 15;191(12):2149–2152.
   PubMed Web of Science ®Google Scholar
• Martinez Perez-Crespo PM, Lopez Cortes LE. Ceftobiprole: a clinical view. Rev Esp Quimioter. 2021 Sep;34(Suppl 1):32–34.
   PubMedGoogle Scholar
• Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 2008 Jan;52(1):37–44.
   PubMed Web of Science ®Google Scholar
• Hamed K, Engelhardt M, Jones ME, et al. Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, phase III trial. Future Microbiol. 2020;15(1):35–48.
   PubMed Web of Science ®Google Scholar
• Morosini MI, Diez-Aguilar M, Canton R. Mechanisms of action and antimicrobial activity of ceftobiprole. Rev Esp Quimioter. 2019 Sep;32 Suppl 3:3–10.
   PubMed Web of Science ®Google Scholar
• Liapikou A, Cilloniz C, Torres A. Ceftobiprole for the treatment of pneumonia: a European perspective. Drug Des Devel Ther. 2015;9:4565–4572.
   PubMedGoogle Scholar
• Casapao AM, Davis SL, Barr VO, et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014 May;58(5):2541–2546.
   PubMed Web of Science ®Google Scholar
• Arshad S, Huang V, Hartman P, et al. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study. Int J Infect Dis. 2017 Apr;57:27–31.
   PubMed Web of Science ®Google Scholar
• Burnett YJ, Echevarria K, Traugott KA. Ceftaroline as Salvage Monotherapy for Persistent MRSA Bacteremia. Ann Pharmacother. 2016 Dec;50(12):1051–1059.
   PubMed Web of Science ®Google Scholar
• Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005 Feb 1;40(3):374–380.
   PubMed Web of Science ®Google Scholar
• Billeter M, Zervos MJ, Chen AY, et al. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis. 2008 Feb 15;46(4):577–583.
   PubMed Web of Science ®Google Scholar
• Werth BJ, Jain R, Hahn A, et al. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen. Clin Microbiol Infect. 2018 Apr;24(4):429 e1–29 e5.
   PubMed Web of Science ®Google Scholar
• Werth BJ, Ashford NK, Penewit K, et al. Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2021 Jun;27(6):910 e1–10 e8.
   Web of Science ®Google Scholar
• Stryjewski ME, Lentnek A, O’Riordan W, et al. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis. 2014. 14. doi:https://doi.org/10.1186/1471-2334-14-14
   Google Scholar
• Holland TL, Chambers HF, and Boucher HW, et al. Considerations for clinical trials of Staphylococcus aureus bloodstream infection in adults. Clin Infect Dis. 2019 Feb 15;68(5):865–872.
   PubMed Web of Science ®Google Scholar
• A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial. 2020. Accessed 15 10 2021. [ cited; Available from: https://clinicaltrials.gov/ct2/show/results/NCT02208063
   Google Scholar
• Hashemian SMR, Farhadi T, Ganjparvar M. Linezolid: a review of its properties, function, and use in critical care. Drug Des Devel Ther. 2018;12:1759–1767.
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009 Jan 15;48(2):203–212.
   PubMed Web of Science ®Google Scholar
• Senior K. FDA issue linezolid warning. Lancet Infect Dis. 2007;7(5):310.
   Web of Science ®Google Scholar
• Kemnic TR, Coleman M, Trimethoprim Sulfamethoxazole, StatPearls, 2021; Treasure Island (FL)
   Google Scholar
• Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992 Sep 1;117(5):390–398.
   PubMed Web of Science ®Google Scholar
• Paul M, Bishara J, Yahav D, et al. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ. 2015 May 14;350:h2219.
   PubMed Web of Science ®Google Scholar
• Wehrli W. Rifampin: mechanisms of action and resistance. Rev Infect Dis. 1983 Jul-Aug;5(Suppl 3):S407–11.
   PubMedGoogle Scholar
• Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev. 2010 Jan;23(1):14–34.
   PubMed Web of Science ®Google Scholar
• Zimmerli W, Sendi P. Role of rifampin against Staphylococcal biofilm infections in vitro, in animal models, and in orthopedic-device-related infections. Antimicrob Agents Chemother. 2019 Feb;63(2). https://doi.org/10.1128/AAC.01746-18
   PubMed Web of Science ®Google Scholar
• Jorgensen NP, Skovdal SM, Meyer RL, et al. Rifampicin-containing combinations are superior to combinations of vancomycin, linezolid and daptomycin against Staphylococcus aureus biofilm infection in vivo and in vitro. Pathog Dis. 2016 Jun;74(4):ftw019.
   PubMed Web of Science ®Google Scholar
• Darouiche RO, Hamill RJ. Antibiotic penetration of and bactericidal activity within endothelial cells. Antimicrob Agents Chemother. 1994 May;38(5):1059–1064.
   PubMed Web of Science ®Google Scholar
• Bayer AS, Lam K. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J Infect Dis. 1985 Jan;151(1):157–165.
   PubMed Web of Science ®Google Scholar
• Thwaites GE, Scarborough M, and Szubert A, et al., Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 391(10121): 668–678. 2018.
   PubMed Web of Science ®Google Scholar
• Bush K, Bradford PA. beta-Lactams and beta-Lactamase Inhibitors: an Overview. Cold Spring Harb Perspect Med. 2016 Aug 1;6(8). DOI:https://doi.org/10.1101/cshperspect.a025247
   Google Scholar
• Pandey N, Cascella M, Beta Lactam Antibiotics, StatPearls, 2021; Treasure Island (FL)
   Google Scholar
• Tang SS, Apisarnthanarak A, Hsu LY. Mechanisms of beta-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria. Adv Drug Deliv Rev. 2014 Nov 30;78:3–13.
   PubMed Web of Science ®Google Scholar
• Beck WD, Berger-Bachi B, Kayser FH. Additional DNA in methicillin-resistant Staphylococcus aureus and molecular cloning of mec-specific DNA. J Bacteriol. 1986 Feb;165(2):373–378.
   PubMed Web of Science ®Google Scholar
• Barber KE, Ireland CE, Bukavyn N, et al. Observation of “seesaw effect” with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. Infect Dis Ther. 2014 Jun;3(1):35–43.
   PubMedGoogle Scholar
• Tong SYC, Lye DC, Yahav D, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal beta-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA. 2020 Feb 11;323(6):527–537.
   PubMed Web of Science ®Google Scholar
• Eljaaly K, Alshehri S, Erstad BL. Systematic review and meta-analysis of the safety of Antistaphylococcal Penicillins compared to Cefazolin. Antimicrob Agents Chemother. 2018 Apr;62(4). DOI:https://doi.org/10.1128/AAC.01816-17
   Google Scholar
• Johnson TM, Molina KC, Miller MA, et al. Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care. Int J Antimicrob Agents. 2021 Apr;57(4):106310.
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moise PA, Casapao AM, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther. 2014 Oct 1;36(10):1317–1333.
   PubMed Web of Science ®Google Scholar
• Geriak M, Haddad F, Rizvi K, et al. Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-Resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2019 May;63(5). doi:https://doi.org/10.1128/AAC.02483-18
   PubMed Web of Science ®Google Scholar
• Silver LL. Fosfomycin: mechanism and Resistance. Cold Spring Harb Perspect Med. 2017 Feb 1;7(2). DOI:https://doi.org/10.1101/cshperspect.a025262
   Google Scholar
• Del Rio A, Gasch O, Moreno A, et al. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. Clin Infect Dis. 2014 Oct 15;59(8):1105–1112.
   PubMed Web of Science ®Google Scholar
• Pericas JM, Moreno A, Almela M, et al. Efficacy and safety of fosfomycin plus imipenem versus vancomycin for complicated bacteraemia and endocarditis due to methicillin-resistant Staphylococcus aureus: a randomized clinical trial. Clin Microbiol Infect. 2018 Jun;24(6):673–676.
   PubMed Web of Science ®Google Scholar
• Garcia-de-la-maria C, Gasch O, Garcia-Gonzalez J, et al. The combination of daptomycin and fosfomycin has synergistic, potent, and rapid bactericidal activity against methicillin-resistant staphylococcus aureus in a rabbit model of experimental endocarditis. Antimicrob Agents Chemother. 2018 Jun;62(6). doi:https://doi.org/10.1128/AAC.02633-17
   Google Scholar
• Pujol M, Miro JM, Shaw E, et al. Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial. Clin Infect Dis. 2021 May 4;72(9):1517–1525.
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Karakawa WW, Vann WF, et al. Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis. 1984;2(2):85–91.
   PubMed Web of Science ®Google Scholar
• Boyle-Vavra S, Li X, Alam MT, et al. USA300 and USA500 clonal lineages of Staphylococcus aureus do not produce a capsular polysaccharide due to conserved mutations in the cap5 locus. mBio. 2015 Apr 7;6(2). DOI:https://doi.org/10.1128/mBio.02585-14
   Web of Science ®Google Scholar
• Diekema DJ, Richter SS, Heilmann KP, et al. Continued emergence of USA300 methicillin-resistant Staphylococcus aureus in the United States: results from a nationwide surveillance study. Infect Control Hosp Epidemiol. 2014 Mar;35(3):285–292.
   PubMed Web of Science ®Google Scholar
• Lee JC, Park JS, Shepherd SE, et al. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun. 1997 Oct;65(10):4146–4151.
   PubMed Web of Science ®Google Scholar
• Fattom AI, Sarwar J, Ortiz A, et al. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun. 1996 May;64(5):1659–1665.
   PubMed Web of Science ®Google Scholar
• Benjamin DK, Schelonka R, White R, et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J Perinatol. 2006 May;26(5):290–295.
   PubMed Web of Science ®Google Scholar
• Rupp ME, Holley HP Jr., Lutz J, et al. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2007 Dec;51(12):4249–4254.
   PubMed Web of Science ®Google Scholar
• Nabi Biopharmaceuticals Announces Results of StaphVAX® Confirmatory Phase III Clinical Trial. 2005. Accessed 5 11 2021. [ cited; Available from: https://www.sec.gov/Archives/edgar/data/72444/000119312505214434/dex99.htm
   Google Scholar
• Peacock SJ, Moore CE, Justice A, et al. Virulent combinations of adhesin and toxin genes in natural populations of Staphylococcus aureus. Infect Immun. 2002 Sep;70(9):4987–4996.
   PubMed Web of Science ®Google Scholar
• Colque-Navarro P, Palma M, Soderquist B, et al. Antibody responses in patients with staphylococcal septicemia against two Staphylococcus aureus fibrinogen binding proteins: clumping factor and an extracellular fibrinogen binding protein. Clin Diagn Lab Immunol. 2000 Jan;7(1):14–20.
   PubMedGoogle Scholar
• Siboo IR, Cheung AL, Bayer AS, et al. Clumping factor A mediates binding of Staphylococcus aureus to human platelets. Infect Immun. 2001 May;69(5):3120–3127.
   PubMed Web of Science ®Google Scholar
• Wolz C, Goerke C, Landmann R, et al. Transcription of clumping factor A in attached and unattached Staphylococcus aureus in vitro and during device-related infection. Infect Immun. 2002 Jun;70(6):2758–2762.
   PubMed Web of Science ®Google Scholar
• Hall AE, Domanski PJ, Patel PR, et al. Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect Immun. 2003 Dec;71(12):6864–6870.
   PubMed Web of Science ®Google Scholar
• Patti JM. A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine. 2004 Dec 6;22(Suppl 1):S39–43.
   PubMedGoogle Scholar
• Weems JJ Jr., Steinberg JP, Filler S, et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2006 Aug;50(8):2751–2755.
   PubMed Web of Science ®Google Scholar
• John JF. Drug evaluation: tefibazumab–a monoclonal antibody against staphylococcal infection. Curr Opin Mol Ther. 2006 ;8(5):455–460.
   PubMedGoogle Scholar
• Falugi F, Kim HK, Missiakas DM, et al. Role of protein A in the evasion of host adaptive immune responses by Staphylococcus aureus. mBio. 2013 Aug 27;4(5):e00575–13.
   PubMed Web of Science ®Google Scholar
• Sun Y, Emolo C, Holtfreter S, et al. Staphylococcal Protein A Contributes to Persistent Colonization of Mice with Staphylococcus aureus. J Bacteriol. 2018 May 1;200(9). DOI:https://doi.org/10.1128/JB.00735-17
   Google Scholar
• Varshney AK, Kuzmicheva GA, Lin J, et al. A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia. PLoS One. 2018;13(1):e0190537.
   PubMed Web of Science ®Google Scholar
• Huynh T, Stecher M, McKinnon J, et al. Safety and Tolerability of 514G3, a true human anti-protein A monoclonal antibody for the treatment of S. aureus bacteremia. Open Forum Infect Dis. 2016;3(suppl_1). DOI:https://doi.org/10.1093/ofid/ofw172.1057
   Google Scholar
• XBiotech announces top-line results for 514G3 antibody therapy in serious Staphylococcus aureus infections. 2017. Accessed 19 10 2021. [ cited; Available from: https://www.globenewswire.com/news-release/2017/04/03/953500/0/en/XBiotech-Announces-Top-Line-Results-for-514G3-Antibody-Therapy-in-Serious-Staphylococcus-aureus-Infections.html
   Google Scholar
• Garzoni C, Kelley WL. Return of the Trojan horse: intracellular phenotype switching and immune evasion by Staphylococcus aureus. EMBO Mol Med. 2011 Mar;3(3):115–117.
   PubMed Web of Science ®Google Scholar
• Peyrusson F, Tulkens PM, Van Bambeke F. Cellular pharmacokinetics and intracellular activity of gepotidacin against staphylococcus aureus isolates with different resistance phenotypes in models of cultured phagocytic cells. Antimicrob Agents Chemother. 2018 Apr;62(4). DOI:https://doi.org/10.1128/AAC.02245-17
   Google Scholar
• Lehar SM, Pillow T, Xu M, et al. Novel antibody–antibiotic conjugate eliminates intracellular S. aureus. Nature. 2015;527(7578):323–328.
   PubMed Web of Science ®Google Scholar
• Staben LR, Koenig SG, Lehar SM, et al. Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates. Nat Chem. 2016 Dec;8(12):1112–1119.
   PubMed Web of Science ®Google Scholar
• Zhou C, Lehar S, Gutierrez J, et al. Pharmacokinetics and pharmacodynamics of DSTA4637A: a novel THIOMAB antibody antibiotic conjugate against Staphylococcus aureus in mice. MAbs. 2016;8(8):1612–1619.
   PubMed Web of Science ®Google Scholar
• Peck M, Rothenberg Michael E, Deng R, et al. A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti-Staphylococcus aureus Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers. Antimicrob Agents Chemother. 2019;63(6):e02588–18.
   PubMed Web of Science ®Google Scholar
• Rymut SM, Deng R, Owen R, et al. 1305 comparison of pharmacokinetics of DSTA4637S, a novel THIOMAB(TM) antibody-antibiotic conjugate, in patients with Staphylococcus aureus bacteremia receiving standard-of-care antibiotics with pharmacokinetics in healthy volunteers. Open Forum Infect Dis. 2020;7(Suppl 1):S666–S67.
   Google Scholar
• Jun SY, Jung GM, Son JS, et al. Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK. Antimicrob Agents Chemother. 2011 Apr;55(4):1764–1767.
   PubMed Web of Science ®Google Scholar
• Jun SY, Jung GM, Yoon SJ, et al. Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1. Int J Antimicrob Agents. 2013 Feb;41(2):156–161.
   PubMed Web of Science ®Google Scholar
• Kim N-H, Park Wan B, Cho Jeong E, et al. Effects of phage endolysin SAL200 combined with antibiotics on Staphylococcus aureus infection. Antimicrob Agents Chemother. 2018;62(10):e00731–18.
   PubMed Web of Science ®Google Scholar
• Jun SY, Jung GM, Yoon SJ, et al. Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient. Antimicrob Agents Chemother. 2014;58(4):2084–2088.
   PubMed Web of Science ®Google Scholar
• Jun SY, Jang IJ, and Yoon S, et al. Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a single intravenous administration among healthy volunteers. Antimicrob Agents Chemother. 2017 Jun;61(6). DOI:https://doi.org/10.1128/AAC.02629-16
   PubMed Web of Science ®Google Scholar
• A study to evaluate the safety, PK, PD, immunogenicity of N-Rephasin® SAL200 in healthy male Volunteers. 2021. Accessed 5 11 2021. [ cited; Available from: https://clinicaltrials.gov/ct2/show/results/NCT03446053
   Google Scholar
• Phase iia clinical study of N-Rephasin® SAL200. 2021. Accessed 5 11 2021. [ cited; Available from: https://clinicaltrials.gov/ct2/show/results/NCT03089697
   Google Scholar
• Schuch R, Lee HM, Schneider BC, et al. Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia. J Infect Dis. 2014 May 1;209(9):1469–1478.
   PubMed Web of Science ®Google Scholar
• Schuch R, Khan BK, and Raz A, et al. Bacteriophage lysin CF-301, a potent antistaphylococcal biofilm agent. Antimicrob Agents Chemother. 2017 Jul;61(7):e02666–16.
   PubMed Web of Science ®Google Scholar
• Indiani C, Sauve K, Raz A, et al. The antistaphylococcal lysin, CF-301, activates key host factors in human blood to potentiate methicillin-resistant staphylococcus aureus bacteriolysis. Antimicrob Agents Chemother. 2019 Apr;63(4). doi:https://doi.org/10.1128/AAC.02291-18
   Google Scholar
• Watson A, Sauve K, Cassino C, et al. Exebacase demonstrates in vitro synergy with a broad range of antibiotics against both methicillin-resistant and methicillin-susceptible staphylococcus aureus. Antimicrob Agents Chemother. 2020 Jan 27;64(2). DOI:https://doi.org/10.1128/AAC.01885-19
   Web of Science ®Google Scholar
• Exebacase Pipeline. 2021. Accessed 11 11 2021. [ cited; Available from: https://www.contrafect.com/pipeline/exebacase
   Google Scholar
• Fowler VG Jr., Das AF, and Lipka-Diamond J, et al. Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis. J Clin Invest. 2020 Jul 1;130(7):3750–3760.
   PubMed Web of Science ®Google Scholar
• Stewart CL, Turner MS, Frens JJ, et al. Real-world experience with oritavancin therapy in invasive gram-positive infections. Infect Dis Ther. 2017 Jun;6(2):277–289.
   PubMed Web of Science ®Google Scholar
• Tice A. Oritavancin: a new opportunity for outpatient therapy of serious infections. Clin Infect Dis. 2012 Apr;54(Suppl 3):S239–43.
   PubMedGoogle Scholar
• Oritavancin for Staphylococcus Aureus Infections in Opioid Users. 2018. Accessed 21 1 2022. [ cited; Available from: https://clinicaltrials.gov/ct2/show/NCT03761953
   Google Scholar
• Hall RG 2nd, Smith WJ, Putnam WC, et al. An evaluation of tedizolid for the treatment of MRSA infections. Expert Opin Pharmacother. 2018 Sep;19(13):1489–1494.
   PubMed Web of Science ®Google Scholar
• Renzoni A, Kelley WL, Rosato RR, et al. Molecular bases determining daptomycin resistance-mediated resensitization to beta-lactams (seesaw effect) in methicillin-resistant staphylococcus aureus. Antimicrob Agents Chemother. 2017 Jan;61(1). doi:https://doi.org/10.1128/AAC.01634-16
   Google Scholar
• Gu J, Xu W, Lei L, et al. LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model efficiently against lethal methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol. 2011 Jan;49(1):111–117.
   PubMed Web of Science ®Google Scholar
• Channabasappa S, Chikkamadaiah R, Durgaiah M, et al. Efficacy of chimeric ectolysin P128 in drug-resistant Staphylococcus aureus bacteraemia in mice. J Antimicrob Chemother. 2018 Dec 1;73(12):3398–3404.
   PubMed Web of Science ®Google Scholar
• Yang H, Zhang H, Wang J, et al. A novel chimeric lysin with robust antibacterial activity against planktonic and biofilm methicillin-resistant Staphylococcus aureus. Sci Rep. 2017 Jan 9;7:40182.
   PubMed Web of Science ®Google Scholar
• ContraFect announces U.S. FDA grants breakthrough therapy designation to exebacase for the treatment of methicillin-resistant staphylococcus aureus (mrsa) bacteremia, including right-sided endocarditis. 2020. Accessed 11 11 2021. [ cited; Available from: https://www.globenewswire.com/en/news-release/2020/02/24/1989110/0/en/ContraFect-Announces-U-S-FDA-Grants-Breakthrough-Therapy-Designation-to-Exebacase-for-the-Treatment-of-Methicillin-Resistant-Staphylococcus-aureus-MRSA-Bacteremia-Including-Right-S.html
   Google Scholar
• Rose W, Fantl M, Geriak M, et al. Current paradigms of combination therapy in methicillin-resistant staphylococcus aureus (mrsa) bacteremia: does it work, which combination, and for which patients? Clin Infect Dis. 2021 Dec 16;73(12):2353–2360.
   PubMed Web of Science ®Google Scholar